---
title: "Sunshine Biopharma, Inc. (SBFM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SBFM.US.md"
symbol: "SBFM.US"
name: "Sunshine Biopharma, Inc."
industry: "Biotechnology"
---

# Sunshine Biopharma, Inc. (SBFM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [unshinebiopharma.com](https://unshinebiopharma.com) |

## Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescri...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:13.000Z

**Overall: C (0.41)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 165 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.24% |  |
| Net Profit YoY | -41.81% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.24 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.74M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 37.32M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -24.35% | E |
| Profit Margin | -16.06% | D |
| Gross Margin | 32.64% | C |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.24% | B |
| Net Profit YoY | -41.81% | D |
| Total Assets YoY | 4.76% | C |
| Net Assets YoY | -3.35% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -622.83% | E |
| OCF YoY | 13.24% | B |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.21 | A |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.15% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Sunshine Biopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-24.35%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-16.06%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "32.64%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.24%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-41.81%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.76%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.35%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-622.83%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "13.24%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.21",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.15%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.96 | 192/605 | - | - | - |
| PB | 0.24 | 12/605 | 0.30 | 0.26 | 0.21 |
| PS (TTM) | 0.15 | 5/605 | 0.19 | 0.18 | 0.14 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-18T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.17 |
| Highest Target | 6.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/SBFM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SBFM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SBFM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.